- Home
- DBRG vs SUPN Comparison
DBRG vs SUPN Comparison
Compare DBRG & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DBRG | SUPN |
|---|---|---|
| Founded | 1991 | 2005 |
| Country | United States | United States |
| Employees | 311 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.0B |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | DBRG | SUPN |
|---|---|---|
| Price | $15.76 | $43.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $16.00 | ★ $61.60 |
| AVG Volume (30 Days) | ★ 2.0M | 535.3K |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.26% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $392,755,000.00 |
| Revenue This Year | $373.39 | $22.70 |
| Revenue Next Year | $8.23 | $19.14 |
| P/E Ratio | $252.25 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.94 | $31.16 |
| 52 Week High | $15.76 | $59.68 |
Technical Indicators
Market Signals| Indicator | DBRG | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 67.88 | 35.48 |
| Support Level | $15.33 | $43.67 |
| Resistance Level | N/A | $52.36 |
| Average True Range (ATR) | 0.04 | 1.46 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 84.21 | 25.42 |
Price Performance
Historical ComparisonAbout DBRG DigitalBridge Group Inc.
DigitalBridge Group Inc is a developer of alternative asset manager dedicated to investing in digital infrastructure. The company's platform invests in and operates businesses across the digital ecosystem, including cell towers, data centres, fiber, small cells, and edge infrastructure, to provide clients with funds for digital infrastructure real estate infrastructure.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.